NGN Capital — 2009 Investments

2 investments dated 2009 · listed companies and verified rows first · show all

Vivaldi Biosciencesvivaldibiosciences.comJan 2009✓ verified

Vivaldi Biosciences develops Delta NS1 vaccines designed to protect against epidemic and pandemic viral respiratory diseases.

BiotechHealthtechMedical DevicesFort Collins, US

Peter Palese(Founder & Scientific Advisor)Adolfo García-Sastre(Founder & Scientific Advisor)Elliott Kieff(Founder & Scientific Advisor)William Wick(CEO, Board Member and Managing Director)

Co-investorsBay City Capital

Cerapedicscerapedics.com in 𝕏Apr 2009 · $15M

Cerapedics develops P-15 peptide enhanced bone graft products, marketed as bone growth accelerators, for spinal fusion procedures.

BiotechHealthtechMedical DevicesWestminster, US

Andrew J. Tofe(Director)in Britt Pearson(Executive Officer)inJeff Marx(Executive Officer)in Glen Kashuba(Executive Officer, Director)inJerome Connor(Executive Officer)inAndrew Handwerker(Executive Officer)

Co-investorsRevelation Partners OrbiMed

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.